Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant

Shusuke Yagi(Tokushima University), Masataka Sata(Tokushima University), Munkhtsetseg Tserensonom(Tokushima University), Takayuki Ise(Tokushima University Hospital), Muneyuki Kadota, Yusuke Osaki(Tokushima University), Yutaka Kawabata(Osaka University of Pharmaceutical Sciences), Daiju Fukuda(Osaka Metropolitan University), Takeshi Soeki(Tokushima University), Koji Yamaguchi(University of Occupational and Environmental Health Japan), Hirotsugu Yamada(Tokushima University Hospital), Yoshihito Saijo(Tokushima University Hospital), Tomoya Hara(Tokushima University Hospital), Rie Ueno(Tokushima University), Hiromu Yamazaki(Tokushima University), Tomomi Matsuura(Keio University), Tetsuzo Wakatsuki(Tokushima University), Kenya Kusunose(University of the Ryukyus)
The Journal of Medical Investigation
January 1, 2022
Cited by 2


Related Papers